Type 1 diabetes mellitus: primary, secondary, and tertiary prevention

The Mount Sinai Journal of Medicine, New York
Jennifer BollykyCarla J Greenbaum

Abstract

We have entered the era of clinical trials to prevent type 1 diabetes mellitus (T1DM). Before 1922, when insulin was first given to a patient with diabetes, a diagnosis of T1DM was considered a death sentence. Advances in treatment for subjects with diabetes are not yet sufficient to prevent the deleterious impact of diabetes on both day-to-day activities and the early morbidity and mortality still associated with the disease. We now understand a great deal about blood glucose regulation and potential health complications associated with long-term T1DM, but the mystery of why, or the pathogenesis of this devastating disease, remains elusive. Great strides toward unraveling this mystery have been made over the past several decades. Even without definitive answers, we are moving from the period of discovery and animal research to the era of clinical trials. In this review, we wish to convey the palpable excitement in the field. It is time to determine if we can safely change the course of T1DM.

References

Apr 1, 1992·The Journal of Clinical Investigation·L C HarrisonP G Colman
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·S J KimG T Nepom
Jan 1, 1985·Acta Endocrinologica. Supplementum·O K Faber
Oct 12, 1974·Lancet·J NerupA Svejgaard
Dec 21, 1974·Lancet·M A MenserJ A Burgess
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·L ChatenoudJ F Bach
Mar 1, 1996·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·A K Foulis
Sep 1, 1996·Diabetologia·T Mandrup-Poulsen
Aug 17, 1999·The Journal of Clinical Investigation·S A LitherlandM J Clare-Salzler
Sep 9, 1999·The American Journal of Clinical Nutrition·A P Simopoulos
Nov 24, 1999·The Journal of Clinical Investigation·M PeakmanR M Chicz
Jun 3, 2000·Annual Review of Immunology·E M Shevach
Mar 29, 2001·Diabetes·C J GreenbaumUNKNOWN Disease Prevention Trial of Type I Diabetes Study Group
May 31, 2002·The New England Journal of Medicine·UNKNOWN Diabetes Prevention Trial--Type 1 Diabetes Study Group
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Aug 8, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Carla J Greenbaum
Sep 27, 2002·Diabetes/metabolism Research and Reviews·Philippe Passa
Apr 30, 2003·Diabetes·Polly J BingleyPatricia W Mueller
Jun 6, 2003·The New England Journal of Medicine·David M NathanUNKNOWN Epidemiology of Diabetes Interventions and Complications Research Group
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Jill M NorrisMarian Rewers
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Anette-G ZieglerEzio Bonifacio
Dec 12, 2003·The American Journal of Clinical Nutrition·Lars C SteneUNKNOWN Norwegian Childhood Diabetes Study Group

❮ Previous
Next ❯

Citations

Sep 11, 2009·Autonomic & Autacoid Pharmacology·P J Fitzgerald
Mar 31, 2015·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Yesica GarciafigueroaNick Giannoukakis
Jul 1, 2006·Biomedical Engineering Online·A Boutayeb, A Chetouani
Jul 3, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Vedran SavićMišo Šabović

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.